The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression.

ABSTRACT:

Background

Recent data suggests that HER2-targeted treatment is efficacious in urothelial carcinoma (UC). We investigated the genomic, transcriptomic, and immune landscapes and clinical outcomes in UC segmented by ERBB2 expression.

Methods

NextGen DNA/RNA sequencing was performed for 4743 UC tumors. A total of 3% (124/4125) of tumors had HER2 IHC and whole transcriptome sequencing (WTS) data. ERRB2-high and -low tumors were defined by ≥75th and <25th percentiles of ERBB2 expression, respectively. PD-L1 (SP142) positive staining was defined as ≥2+ and ≥5%. HER2 (4B5) positive staining was defined as ≥3+ and >10% or 2+ and >10% with positive HER2 in situ hybridization (ISH).

Results

Of the patients who were ERBB2-high, 79% (61/77) were HER2 p

SUBMITTER: Hadadi A 

PROVIDER: S-EPMC10742086 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature